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Abstract
Introduction: Urinary microRNAs (miRNAs) are emerging as a clinically useful tool for early and non-invasive detection of various types of cancer. 
The aim of this study was to evaluate whether let-7 family miRNAs differ in their urinary concentrations between renal cell carcinoma (RCC) cases 
and healthy controls.
Materials and methods: In the case-control study, 69 non-metastatic clear-cell RCC patients and 36 gender/age-matched healthy controls were 
prospectively enrolled. Total RNA was purified from cell-free supernatant of the 105 first morning urine specimens. Let-7 family miRNAs were deter-
mined in cell-free supernatant using quantitative miRNA real-time reverse-transcription PCR and absolute quantification approach. 
Results: Concentrations of all let-7 miRNAs (let-7a, let-7b, let-7c, let-7d, let-7e and let-7g) were significantly higher in urine samples obtained from 
RCC patients compared to healthy controls (P < 0.001; P < 0.001; P = 0.005; P = 0.006; P = 0.015 and P = 0.002, respectively). Subsequent ROC 
analysis has shown that let-7a concentration possesses good ability to differentiate between cases and controls with area under curve being 0.8307 
(sensitivity 71%, specificity 81%).
Conclusions: We have shown that let-7 miRNAs are abundant in the urine samples of patients with clear-cell RCC, and out of six let-7 family mem-
bers, let-7a outperforms the others and presents promising non-invasive biomarker for the detection of RCC.
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Renal cell carcinoma (RCC) accounts for 2–3% of all 
malignant tumours. There are several histological 
subtypes of RCC, with clear-cell (or conventional) 
histological type being the most frequent, pre-
senting 70% – 80% of RCC cases (1). Despite a 
steady decrease in mortality rates, RCC remains 
one of the most lethal urological malignancies, 
with 5-year relative survival 72% (1). For advanced 
and metastatic RCCs (32% of all diagnosed cases), 
5-year relative survival descends to 66% and 12%, 
respectively. Biomarkers for early detection of RCC 
are therefore necessary as there is no reliable diag-
nostic modality other than radiological imaging. 
MicroRNAs (miRNAs) are short noncoding RNAs 
that regulate gene expression at the posttranscrip-
tional level. They are involved in the number of 
critical biological processes including carcinogen-
esis. Besides tumour tissues, they are also present 
in different body fluids (e.g. serum, plasma, urine) 
with a high degree of stability indicating their ex-
tensive biomarker potential (2). Although variety 
of circulating miRNAs has been proposed as bio-
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markers of RCC, urinary miRNAs have been mostly 
studied in bladder and prostate cancer (3).
The miRNA let-7 family is widely accepted as a tu-
mour suppressor miRNA with important role in 
the regulation of cell cycle, cell differentiation and 
apoptosis (4). Downregulation of the members of 
let-7 family has been observed in various types of 
tumour tissue including RCC (5). Less frequent, up-
regulation of certain let-7 family members has also 
been observed, suggesting that let-7 does not 
play a tumour suppressor function under all cir-
cumstances and in all tissues (6). Higher levels of 
let-7 miRNAs in urine has been reported in bladder 
cancer (7). There are no data about urinary let-7 
miRNAs in RCC, but increased urinary levels of 
some of the let-7 family members were found in 
patients with autosomal dominant polycystic kid-
ney disease suggesting their abundance in urine 
and therefore also potential utility in other renal 
diseases such as cancer (8). 
Based on that, we hypothesize, that let-7 family 
miRNAs differ in their concentrations in urine sam-
ples of RCC patients and heathy individuals, and 
could be potentially useful as diagnostic biomark-
ers of RCC. To this end, the aim of our study was to 
determine concentration of let-7 miRNAs in cell-
free supernatant in group of prospectively en-
rolled patients with non-metastatic clear cell RCC 
and group of healthy controls, statistically evalu-
ate the differences in concentrations between the 
groups and their ability to distinguish between 
RCC cases and healthy controls.
Material and methods
Study design and subjects
Between May 2015 and December 2016, adults un-
dergoing partial or radical nephrectomy for RCC at 
Department of Urology, University Hospital Brno 
(UHB) were prospectively screened for participa-
tion in this observational case-control study. Inclu-
sion criteria included: histologically proven clear-
cell RCC, no distant metastasis or nodal involve-
ment. Exclusion criteria included: active malignan-
cy other than RCC, history of any malignancy, uri-
nary tract infection, foreign bodies in urinary tract 
and urolithiasis. Urine samples of the cases were 
collected prior to surgically treatment. In the same 
time period participants of the control group were 
enrolled. Healthy controls included patients surgi-
cally treated at UHB for benign urological condi-
tions like urethral stricture, phimosis, undescend-
ed testicle, stress urinary incontinence, hydrocele, 
benign prostatic hyperplasia, urethral caruncula, 
vesical neck sclerosis, simple renal cyst. Patients 
with active malignancy or history of any cancer, 
urinary tract infection, and foreign bodies in uri-
nary tract or urolithiasis were excluded from con-
trol group. Urine samples of the control group 
were collected during regular post-operative fol-
low-up visits. Study was approved by the Ethic 
committee at UHB and all participants signed in-
formed consent before entering the study.
Out of 76 RCC patients approached, 2 declined to 
participate in the study, 15 patients were not in-
cluded due to papillary or chromophobe histolog-
ical type of RCC proved after surgery. Since we 
were not focused on the follow-up of patients, 
there was no additional drop-out from our study. 
All 36 healthy controls approached, agreed to par-
ticipate on our study. Finally, 69 patients diag-
nosed with non-metastatic clear-cell RCC and 36 
healthy controls were enrolled. Epidemiological 
and clinical characteristics of the cases and con-
trols groups are summarized in Table 1. 
Urine sampling and RNA isolation
The first morning urine samples were collected in 
15 mL tubes (Sarstedt AG & Co., Numbrecht, Ger-
many) with EDTA used for nucleic acid preserva-
tion and kept at 4 oC till further processing. As the 
next step, urine samples were centrifuged at 4 °C 
at 2000g for 15 minutes, and the cell-free superna-
tant was then collected and stored at − 80 °C until 
analysis. Before RNA isolation another centrifuga-
tion of urine sample was performed at 4 °C at 
12,000g for 15 minutes. Total RNA from 1 mL of 
cell-free supernatant was isolated using manual 
column-based method, Urine microRNA Purifica-
tion Kit (Norgen Biotek, Thorold, Ontario, Canada) 
according to the manufacturer’s instructions. RNA 
concentration and purity was evaluated using Na-
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primer and the TaqMan® MicroRNA Reverse Tran-
scription Kit (Thermo Fisher Scientific) accordingly 
to manufacturer’s recommendations. Real-time 
PCR was performed in 20-µL PCR reaction with 
1.33 µL of RT product using specific TaqMan® Mi-
croRNA assays (let-7a: ID000377, let-7b: ID002619, 
let-7c: ID000379, let-7d: ID002283, let-7e: ID002406, 
let-7g: ID002282; Thermo Fisher Scientific) on 
Roche LightCycler 480 PCR system (Roche, Basel, 
Switzerland) accordingly to manufacturer’s recom-
mendations. The reactions were carried out in a 
96-well optical plate at 95 °C for 10 minutes, fol-
lowed by 40 cycles of 95 °C for 15 seconds and 60 
°C for 1 minute. All reactions were run in dupli-
cates. After the reaction, the treshold cycle (Ct) val-
ues were determined using the fixed threshold 
settings, and the mean Ct values were calculated 
from duplicates. For each miRNA assay, a dilution 
series of synthetic miRNA oligo (IDT, Coralville, 
Iowa, USA) were carried out in parallel with qRT-
PCR of biological samples to generate an absolute 
standard curve for quantification of let-7 concen-
trations. We also included inter-plate calibrator on 
each plate for each assay enabling us to correct for 
inter-plate variability. Quantitatively all measure-
ments were standardized by use of the same 
amount of total RNA (10 ng) entering the reverse 
transcription and PCR reaction. Ct values of bio-
logical samples were converted to absolute con-
centration of miRNAs in the cell-free supernatant 
of the urine (fmol/L) based on relevant calibration 
curve equation (Figure 1) based on the recently 
described approach (9).
Statistical analysis
Statistical analysis was performed with GraphPad 
Prism version 6.00 for Windows (GraphPad Soft-
ware, La Jolla California USA, www.graphpad.com). 
To compare urinary concentrations of miRNAs be-
tween RCC cases and healthy controls non-para-
metric Mann-Whitney U test was used since our 
experimental data do not follow a normal distribu-
tion. A P-value < 0.01 was considered statistically 
significant. The ROC analysis was performed to 
evaluate the ability of studied miRNAs to distin-
guish between urine of RCC patients and healthy 
controls.
ccRCC patients Healthy controls
N = 69 N = 36
Male (N, proportion) 50 (0.72) 24 (0.67)
Age (years) 66 (33-87) 65 (40-79)
pT stage*
   pT1 54 NA
   pT2 4 NA
   pT3 11 NA
   pT4 0 NA
pN stage*
   pN0 69 NA
   pN1 0 NA
pM stage*
   pM0 69 NA
   pM1 0 NA
Fuhrman grade†
   G1 11 NA
   G2 40 NA
   G3 13 NA
   G4 5 NA
*pT,N,M stages accordingly to American Joint Committee 
on Cancer Staging Manual. †The grading scheme used in 
RCC. RCC - renal cell carcinoma, ccRCC - clear-cell renal cell 
carcinoma, NA - not applicable.
Table 1. Epidemiological and clinical characteristics of study 
subjects.
nodrop 2000 Spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA). Only the samples 
with concentration higher than 5 ng/µL and A260/
A280 higher than 1.3 were further analysed in the 
study. 
Quantitative miRNA real-time 
reverse-transcription PCR
Concentrations of let-7a, let-7b, let-7c, let-7d, let-7e, 
and let-7g were determined by quantitative miR-
NA real-time reverse-transcription PCR (qRT-PCR) 
accordingly to TaqMan MicroRNA assay protocol 
(Thermo Fisher Scientific, Waltham, MA, USA). 
Complementary DNA was synthesized from 10 ng 
of total RNA in 15-µL reverse transcription (RT) re-
action using microRNA-specific stem-loop RT 
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Figure 1. Absolute standard curves for let-7a (A), let-7b (B), let-7c (C), let-7d (D), let-7e (E) and let-7g (F) used for calculation of let-7 mi-
croRNAs concentrations (fmol/L) in the urine samples. E - qPCR reaction efficiency.
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We successfully purified RNA from urine samples 
of 105 subjects enrolled into our study. The con-
centration of RNA ranged from 5.1 to 17.3 with a 
median of 6.7 ng/µL and the purity (A260/A280) 
ranged from 1.3 to 2.0 with a median of 1.5. 
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The concentrations of all 6 miRNAs (let-7a, let-7b, 
let-7c, let-7d, let-7e, and let-7g) were significantly 
higher in urine samples obtained from RCC cases 
compared to healthy controls (P < 0.001; P < 0.001; 
P = 0.005; P = 0.006; P = 0.015 and P = 0.002, re-
spectively; Table 2). Subsequent ROC analysis was 
performed to evaluate ability of urinary miRNAs to 
distinguish between RCC cases and controls. ROC 
curves indicated that urine concentration of let-7a 
possess satisfactory ability to differentiate be-
tween patients and controls with the AUC being 
0.8307 (Figure 2A,B). The remaining let-7 miRNAs 
showed inferior analytical performance (AUC < 
0.75; summarized in Table 2). We further evaluated 
analytical performance of combination of all let-7 
miRNAs with AUC being 0.83. 
Discussion
Noninvasive biomarker of RCC in urine presents a 
significant unmet medical need of urologic oncol-
ogy. To prove our hypothesis that let-7 miRNAs 
concentrations in urine differ between RCC cases 
and healthy controls, we used the case-control de-
sign performed prospectively enabling us to con-
trol pre-analytical conditions, sample handling 
and processing. Common approaches to miRNA 
clinical testing include small RNA sequencing, qRT-
PCR, miRNA microarray, multiplexed miRNA detec-
tion with color-coded probe pairs, and miRNA in 
situ hybridization. We decided to use qRT-PCR, 
since our approach is targeted and this method 
has several advantages in comparison to others: 
Figure 2. Differences of let-7a concentration between RCC patients and controls. 
(A) Absolute concentrations of let-7a was determined by qRT-PCR in urine of RCC patients (N = 69) and healthy individuals (N = 36). 
(B) ROC analysis of let-7a to evaluate the ability to distinguish RCC patients and healthy controls. AUC – area under curve.
miRNA RCC patients Healthy controls P-value AUC Sens . (%) Spec . (%)
let-7a, fmol/L 7.510 (2.668–14.250) 1.525 (0.673–3.368) < 0.001 0.83 71 81
let-7b, fmol/L 3.500 (1.835–6.160) 1.350 (0.1400–2.880) < 0.001 0.75 73 67
let-7c, fmol/L 9.390 (4.090–18.82) 5.115 (2.180–9.253) 0.005 0.67 65 62
let-7d, fmol/L 5.540 (2.450–11.88) 3.505 (1.705–5.145) 0.006 0.66 66 61
let-7e, fmol/L 58.9 (25.03–106.6) 32.35 (15.33–63.60) 0.015 0.65 62 61
let-7g, fmol/L 22.48 (11.46–35.19) 12.89 (5.72–19.64) 0.002 0.69 70 60
Values of MiRNA concentrations are presented as median (interquartile range). AUC - Area under curve; Sens. – Sensitivity; Spec. – 
Specificity.
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high dynamic range, high sensitivity and specifici-
ty, small requests on RNA input, it is widely used in 
clinical diagnostics and comparatively inexpen-
sive.  
In our study, we confirmed our hypothesis, and 
found that urinary concentrations of let-7 miRNAs 
in RCC patients are significantly higher compared 
to healthy controls. Let-7a concentrations enabled 
to discriminate urine of the RCC patients and con-
trols with a sensitivity of 71% and specificity of 
81%, suggesting its diagnostic value for detection 
of RCC. We further evaluated analytical perfor-
mance of combination of all let-7 miRNAs and 
there was no notable increase in AUC values ob-
served in comparison to let-7a used as the only bi-
omarker.
In contrast to bladder or prostate cancer, data 
about urinary miRNAs in RCC are sparse. In the pi-
lot study of von Brandenstein et al. (23 RCC pa-
tients, 5 controls), higher levels of miR-15a were 
found in urine of RCC patients but was undetecta-
ble in oncocytoma, other tumours or urinary in-
fection (10). In the recent study of Guorong et al., 
urinary levels of miR-210 were found to be signifi-
cantly higher in patients with clear-cell RCC (N = 
75) compared to healthy controls (N = 45), with 
sensitivity, specificity and the area under ROC 
curve 57.8%, 80% and 0.76, respectively. In addi-
tion, the expression levels of urinary miR-210 sig-
nificantly decreased one week after surgery (11). 
Based on our results, urinary let-7a indicates supe-
rior analytical performance to urinary miR-210 
studied by Guorong et al. (AUC 0.83 vs. 0.76). Al-
though analytical characteristics of urinary let-7a 
seem to be promising, there are not sufficient for 
clinical application of let-7a as the only biomarker. 
However, we believe, that urinary let-7a could add 
significant diagnostic value if combined with oth-
er emerging biomarkers in RCC or for monitoring 
of the RCC patients with initially increased levels of 
this biomarker. Analogically to other biomarkers in 
various cancers (e.g. carcinoembryonic antigen in 
colorectal cancer), we suppose, that in RCC, secre-
tion of the let-7a presents biological feature of the 
subset and not all RCC cases.
Our study has several limitations, which should be 
discussed. The main limitation is the small group 
of RCC cases and controls and absence of the inde-
pendent validation set. To this end, our study is a 
pilot study showing diagnostic potential of urinary 
let-7a concentrations in detection of RCC, but fur-
ther independent studies are needed to confirm 
our results. Another limitation is absolute quantifi-
cation approach, which we used for determination 
of studied urinary miRNAs disabling to eliminate 
methodical inaccuracies, which could occur in pro-
cessing of every sample and, finally, could bias 
comparisons of different groups of samples. There 
were some transcripts used for normalization of 
urinary miRNAs (e.g. RNU6B or RNU48) (3), but to 
our knowledge there is no consensual reference 
gene. Therefore, we decided to use absolute quan-
tification and to overcome this potential techno-
logical variability or bias, we implemented stand-
ardized protocols for urine samples collection, 
handling and storage. 
In conclusion, we showed that let-7 miRNA family 
members are abundant in the urine cell-free su-
pernatant of patients with clear-cell RCC, and con-
firmed our hypothesis, that let-7 miRNAs have dif-
ferent concentrations in the urine of RCC cases and 
healthy controls. Out of six let-7 members ana-
lysed, let-7a outperforms the others and may be 
considered as a promising noninvasive biomarker 
for the detection of clear-cell RCC. 
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